Skip to main content
JNMA: Journal of the Nepal Medical Association logoLink to JNMA: Journal of the Nepal Medical Association
. 2021 Jan 31;59(233):7–11. doi: 10.31729/jnma.5980

Prevalence of Functional Limitation in COVID-19 Recovered Patients Using the Post COVID-19 Functional Status Scale

Pankaj Pant 1,, Aishana Joshi 2, Babin Basnet 3, Bibek Man Shrestha 3, Navindra Raj Bista 4, Niraj Bam 1, Santa Kumar Das 1
PMCID: PMC7893391  PMID: 34508442

ABSTRACT

Introduction:

COVID-19 is an emerging global health pandemic causing tremendous morbidity and mortality worldwide. Chronic symptoms progressing to poor functional status have been reported in a substantial proportion of COVID-19 patients worldwide. This study aimed to determine the prevalence of functional limitation in COVID-19 recovered patients using the post-COVID-19 functional status scale.

Methods:

A descriptive cross-sectional study was conducted at Tribhuvan University Teaching Hospital. COVID-19 recovered patients with reverse transcription-polymerase chain reaction negative status were included and assessed using the post-COVID-19 functional status scale. Data entry and analysis was done in Statistical Package for the Social Sciences version 20.0. Descriptive statistics were performed.

Results:

A total of 106 patients were included for the final analysis. More than half of the patients (56.6%) reported having no functional limitation (grade 0), while the prevalence of some degree of functional limitation was observed in 46 (43.4%) patients (grade 1 to 4).

Conclusions:

Some form of functional limitation should be anticipated after COVID-19 infection. Post-COVID-19 functional status scale can be a valuable tool in determining the prevalence of functional limitation in COVID-19 recovered patients in acute health care settings. It can potentially guide in planning rehabilitative measures in post-acute care management of COVID-19 survivors.

Keywords: COVID-19, functional status, PCFS scale

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). The first outbreak of SARS-COV2 was reported in Wuhan, Hubei Province in China.1 It was declared a global pandemic by the World Health Organization (WHO).2 The first confirmed case of COVID-19 from Nepal was reported in January 2020. 3

A wide range of pulmonary and extra-pulmonary manifestations have been reported in post-COVID-19 patients.46 Persisting symptoms with subsequent progression to poor functional status have been reported in a substantial proportion of these patients. Acute respiratory distress syndrome (ARDS), prolonged hospitalization, and admission in an Intensive Care Unit (ICU) have been reported among COVID-19 infections in acute care settings.7,8 The physical and mental health assessment in COVID-19 survivors with emphasis on post-acute care has been a recent global health concern.

This study aims to determine the prevalence of functional limitation in COVID-19 recovered patients using the post COVID-19 functional status (PCFS) scale.9

METHODS

This is a descriptive cross-sectional study conducted in the department of Pulmonology and Critical Care at Tribhuvan University Teaching Hospital (TUTH) in December 2019. Ethical approval was taken from Institutional Review Committee, TUTH (Reference no. 152/(6-11)/E2/077/078 dated December 8, 2020). The sample size was calculated as follows:

  • Samples size = n

  • Confidence level (CI) = 95%,

  • For 95% CI, Z-score (Z) = 1.96

  • Level of significance = 5%

  • Sampling error (e) = 10%

  • Prevalence for maximum sample size (p) = 50%

n=Z2pq/e2=(1.96)2×0.5×(10.5)/(0.1)2=96.0496

Taking 10% non-response rate in the calculated sample size = 9.6.

Hence, minimum sample size = 96.04 + 9.6 = 105.64 ≈ 106

A convenient sampling technique was used. COVID-19 survivors with RT-PCR negative status were included in the study. Patients with active COVID-19 infection, known cardiac and/or respiratory co-morbidities with Medical Research Council (MRC) grade >0 and New York Heart Association (NYHA) grade >1 were excluded from the study. Patients with known functional disabilities and known illness likely to progress and limit physical ability like trauma, malignancies, progressive myopathies, and neuropathies were excluded from the study.

A total of 106 patients were included for the final analysis. The functional limitations were observed using the post-COVID-19 functional status (PCFS) scale (Table 1).9

Table 1. The Post COVID-19 functional status scale (PCFS)9.

How much are you currently affected in your everyday life by COVID-19 (Please indicate which one of the following statements applies to the most) Corresponding PCFS scale Grade Interpretation
I have no limitations in my everyday life and no symptoms, pain, depression or anxiety related to the infection. 0 No functional limitations
I have negligible limitations in my everyday life as I can perform all usual duties/activities, although I still have persistent symptoms, pain, depression or anxiety. 1 Negligible functional limitations
I suffer from limitations in my everyday life as I occasionally need to avoid or reduce usual duties/activities or need to spread these over time due to symptoms, pain, depression or anxiety. I am, however, able to perform all activities without any assistance. 2 Slight functional limitations
I suffer from limitations in my everyday life as I am not able to perform all usual duties/activities due to symptoms, pain, depression or anxiety. I am, however, able to take care of myself without any assistance. 3 Moderate functional limitations
I suffer from severe limitations in my everyday life: I am not able to take care of myself and therefore I am dependent on nursing care and/or assistance from another person due to symptoms, pain, depression or anxiety. 4 Severe functional limitations

Patients were graded from 0 to 4 according to the PCFS scale. The patients falling in all grades except grade 0 were observed to have some degree of functional limitation, which was further graded from 1 to 4 into negligible, slight, moderate, and severe groups depending on the severity of functional limitation (Table 1). Data were obtained using a semi-structured questionnaire self-reported by the patients. Data entry and analysis was done in SPSS version 20.0. Descriptive statistics were performed, and results were interpreted in frequency and percentage.

RESULTS

A total of 106 patients with RT-PCR negative status were included for final analysis. The mean age of patients was 38.48±16.20 years, with a range from 22 to 83 years. The highest number of patients was 15-29 years in both sexes (Table 1).

Figure 1. Age distribution of the patients.

Figure 1

There were 73 (68.9%) males and 33 (31.1%) females. Nearly half of the patients (47.2%) were health care workers who comprised doctors (26.4%), nurses (12.3%), and paramedical staff (8.5%). Hypertension was the most common co-morbidity seen in 20 (18.9%) patients, followed by Diabetes mellitus in 15 (14.2%) patients. Seventeen percent of these patients required hospital admission during COVID-19 infection (Table 1).

Table 2. Baseline characteristics of the patients (n = 106).

Characteristics n (%)
Sex  
Male 73 (68.9)
Female 33 (31.1)
Residence  
Kathmandu valley 67 (63.2)
Outside Kathmandu valley 39 (36.8)
Health care workers  
Yes 50 (47.2)
No 56 (52.2)
Occupation  
Doctors 28 (26.4)
Nurses 13 (12.3)
Paramedics 9 (8.5)
Students 15 (14.2)
Business 6 (5.7)
Service 19 (17.9)
Dependent 7 (6.6)
Others 9 (8.5)
Cigarette smoking  
Current smoker 12 (11.3)
Past smoker 23 (21.7)
Never smoked 71 (67)
Co-morbidities  
None 66 (62.3)
Hypertension 20 (18.9)
Diabetes mellitus 15 (14.2)
Post Tuberculosis (TB) sequelae 8 (7.5)
COPD 6 (5.7)
Thyroid disorder 5 (4.7)
Asthma 3 (2.8)
Vaccination  
BCG 85 (80.2)
Pneumococcal (within last 5 years) 5 (4.7)
Influenza (within last 1 year) 14 (13.2)
Need for hospitalization  
Yes 18 (17)
No 88 (83)

During the post-COVID-19 recovery state after RT-PCR negative status, more than half of the patients (56.6%) reported having no functional limitation (PCFS grade 0), while the prevalence of some degree of functional limitation was observed in 46 (43.4%) patients (Table 3).

Table 3. Grading of patients according to the Post COVID-19 Functional Status (PCFS) scale (n = 106).

Post COVID-19 functional status scale grade Interpretation n (%)
Grade 0 No functional limitations 60 (56.6)
Grade 1 Negligible functional limitations 29 (27.3)
Grade 2 Slight functional limitations 13 (12.3)
Grade 3 Moderate functional limitations 2 (1.9)
Grade 4 Severe functional limitations 2 (1.9)

The majority of patients (89.6%) had at least one of the pulmonary or extra-pulmonary symptoms during COVID-19 infection. A minority (11%) did not report any symptoms. Fever was the most predominant symptom observed in two-third of the patients (n=70, 66%) followed by cough in 59 (55.7%) and fatigue in 48 (45.3%) patients (Table 4).

Table 4. Predominant symptoms during COVID-19 infection (n = 106).

Predominant symptoms during COVID-19 infection n (%)
Asymptomatic 11 (10.4)
Fever 70 (66)
Cough 59 (55.7)
Fatigue 48 (45.3)
Loss of smell 45 (42.5)
Loss of taste 40 (37.7)
Shortness of breath 23 (21.7)
Sore throat 15 (14.2)
Chest pain 12 (11.3)
Myalgia 10 (9.4)
Headache 5 (4.7)
Loose stool 4 (3.8)
Abdominal pain 3 (2.8)
Vomiting 2 (1.9)

DISCUSSION

We assessed 106 COVID-19 recovered patients with RT-PCR negative status using the post-COVID-19 functional status (PCFS) scale. PCFS scale is a simple tool developed recently by Klok FA et al.9 to monitor the course of symptoms and its impact on patients' functional status in COVID-19 survivors. PCFS scale covers the full spectrum of functional outcomes and focuses on both limitations in usual duties/activities and lifestyle changes in five scale grades ranging from 0 to 4. Based on the PCFS scale, we observed that during the post-COVID-19 recovery state after RT-PCR negative status, more than half of the patients (56.6%) reported having no functional limitation (PCFS grade 0) while the prevalence of some degree of functional limitation was observed in 46 (43.4%) patients. Nearly one fourth (27.3%) of the patients had negligible functional limitation (PCFS grade 1). Slight functional limitation (PCFS grade 2) was seen in 13 (12.3%) patients. Moderate (PCFS grade 3) and severe functional limitations (PCFS grade 4) were observed in a minority of patients with an equal proportion of patients (n=2, 1. 9%) in each of these groups. We observed that more than 50% of our patients had no functional limitation with corresponding PCFS grade 0. This could have been partly due to the inclusion of a higher number of younger patients in our study. The mean age of patients in our study was 38.48±16.20 years, with the highest number of patients in the age group of 15-29 years in both sexes. Younger patients are reported to have a better outcome as compared to the frail elderly population after COVID-19 infection.1012 Strict isolation protocols, as adapted widely across many countries in the management of COVID-19 patients in hospitals, patients' own residence or at COVID isolation centers, have resulted in a significant reduction of patient's mobility.13 This could be specifically implicated for the decline in functional status in COVID-19 patients during recovery state.

Nearly 90% of patients reported at least one of the clinical symptoms. Fever was the most predominant symptom observed in two-third of the patients (66%) followed by cough (55.7%). Shortness of breath and chest pain were other pulmonary symptoms observed in 21.7% and 11.3% of patients, respectively. Persisting symptoms with subsequent progression to poor functional status have been reported in a substantial proportion of COVID-19 survivors.14,15 Pulmonary function impairment16, mental health problems,17 and reduced quality of life18 to a various extent have been reported in COVID-19 patients. These factors could have a long term impact on physical, mental, social and cognitive health and well being of COVID-19 infected patients, causing a decline in functional status.

The long term consequences of COVID-19 may vary extensively among patients. In view of the massive number of COVID-19 survivors who require long-term follow-up, a simple, easy, reproducible, and cost-effective tool would be vital for proper utilization of resources in post-acute care COVID-19 patients and guide rehabilitative measures. Klok FA et al.9 have recommended using the PCFS scale depending on local conditions in which it is implemented. We used this tool in our study as it is simple and inexpensive and hence, could be specifically beneficial in resource-poor health care settings. We recommend large multi-centre studies with a greater sample size to validate the PCFS scale as a tool for assessing long-term post-COVID-19 functional status in the Nepalese population.

CONCLUSIONS

The physical and mental health effects of SARS-COV2 infection should be anticipated in every COVID-19 patient. Early detection of functional decline with subsequent planning of rehabilitative measures is vital in post-acute care management of COVID-19 patients. PCFS scale is a simple tool in determining the prevalence of functional limitation in COVID-19 recovered patients in acute health care settings. We recommend large multi-centre studies with a longer duration of follow-up to validate the PCFS scale to assess long-term health effects and post COVID-19 functional status in the Nepalese population.

Conflict of Interest

None.

REFERENCES

  • 1.Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. Journal of medical virology. 2020 Apr;92(4):401–2. doi: 10.1002/jmv.25678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet] 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020 Available from:
  • 3.Bastola A, Sah R, Rodriguez-Morales AJ, Lal BK, Jha R, Ojha HC, Shrestha B, Chu DK, Poon LL, Costello A, Morita K. The first 2019 novel coronavirus case in Nepal. The Lancet Infectious Diseases. 2020 Mar 1;20(3):279–80. doi: 10.1016/S1473-3099(20)30067-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. Pulmonary and extra-pulmonary clinical manifestations of COVID-19. Frontiers in Medicine. 2020 Aug 13;7:526. doi: 10.3389/fmed.2020.00526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Goërtz YM, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FV, Houben-Wilke S, Burtin C, Posthuma R, Franssen FM, van Loon N. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ open research. 2020 Oct 1;6(4) doi: 10.1183/23120541.00542-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterization of post-COVID-19 manifestations. International Journal of Clinical Practice. 2020 Nov 3;:e13746. doi: 10.1111/ijcp.13746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Critical Care. 2020 Dec;24(1):1–4. doi: 10.1186/s13054-020-03240-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ferrando C, Suarez-Sipmann F, Mellado-Artigas R, Hernández M, Gea A, Arruti E, Aldecoa C, Martínez-Pallí G, Martínez-González MA, Slutsky AS, Villar J. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive care medicine. 2020 Dec;46(12):2200–11. doi: 10.1007/s00134-020-06192-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Klok FA, Boon GJ, Barco S, Endres M, Geelhoed JM, Knauss S, Rezek SA, Spruit MA, Vehreschild J, Siegerink B. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. European Respiratory Journal. 2020 Jul 1;56(1) doi: 10.1183/13993003.01494-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, Chen X, Luo M, Liang K, Gao S, Zhang Y. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. The Journals of Gerontology: Series A. 2020 Apr 11; doi: 10.1093/gerona/glaa089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, Pearce L, Stechman M, Short R, Price A, Collins JT. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. The Lancet Public Health. 2020 Aug 1;5(8):e444–51. doi: 10.1016/S2468-2667(20)30146-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Chinnadurai R, Ogedengbe O, Agarwal P, Money-Coomes S, Abdurrahman AZ, Mohammed S, Kalra PA, Rothwell N, Pradhan S. Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting-a cohort study. BMC geriatrics. 2020 Dec;20(1):1–1. doi: 10.1186/s12877-020-01803-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Belli S, Balbi B, Prince I, Cattaneo D, Masocco F, Zaccaria S, Bertalli L, Cattini F, Lomazzo A, Dal Negro F, Giardini M. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. European Respiratory Journal. 2020 Oct 1;56(4) doi: 10.1183/13993003.02096-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Goërtz YM, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FV, Houben-Wilke S, Burtin C, Posthuma R, Franssen FM, van Loon N. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ open research. 2020 Oct 1;6(4) doi: 10.1183/23120541.00542-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. Jama. 2020 Aug 11;324(6):603–5. doi: 10.1001/jama.2020.12603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, Jia JL, Li LM, Mao HL, Zhou XM, Luo H. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. E Clinical Medicine. 2020 Aug 1;25:100463. doi: 10.1016/j.eclinm.2020.100463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ma YF, Li W, Deng HB, Wang L, Wang Y, Wang PH, Bo HX, Cao J, Wang Y, Zhu LY, Yang Y. Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19. Journal of affective disorders. 2020 Oct 1;275:145–8. doi: 10.1016/j.jad.2020.06.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Chen KY, Li T, Gong F, Zhang JS, Li XK. Predictors of health-related quality of life and influencing factors for COVID-19 patients, a follow-up at one month. Frontiers in Psychiatry. 2020;11:668. doi: 10.3389/fpsyt.2020.00668. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JNMA: Journal of the Nepal Medical Association are provided here courtesy of Nepal Medical Association

RESOURCES